Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion